+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

This research aims to evaluate the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors SGLT2i in patients with end-stage kidney disease undergoing maintenance hemodialysis. Cardiovascular complications such as heart failure, arrhythmias, and sudden cardiac death are common in this group, often linked to diastolic dysfunction and cardiac fibrosis that current treatments do not adequately address. This Phase 2 randomized controlled trial seeks to determine if SGLT2 inhibitors can improve cardiac function and reduce these risks. Participants will be randomly assigned to one of two groups one receiving standard hemodialysis care without SGLT2 inhibitors, and the other receiving a once-daily oral SGLT2 inhibitor alongside standard care for 12 months. The intervention group will be monitored through advanced cardiac imaging and biomarker assessments at baseline and at 3, 6, and 12 months. The study will assess changes in heart structure and function, myocardial fibrosis, and the frequency of intradialytic hypotension. Throughout the 12-month study, participants will undergo comprehensive evaluations including echocardiography, cardiac MRI, 24-hour heart rhythm monitoring, and laboratory tests. Researchers will track cardiovascular events, hospitalizations, and mortality. Data will be collected at multiple time points to measure outcomes such as changes in left ventricular mass and ejection fraction, fibrosis biomarkers, and incidence of hypotension during dialysis. This thorough monitoring aims to provide new insights into cardiac health in dialysis patients.

Age: 18Years - 70YearsAll GendersPhase 2
1 location
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations